Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

With a potential buyer not working out, Idorsia has adjusted an existing partnership and restructured bonds to raise cash.

The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 4, 2025Idorsia Ltd (SIX: IDIA) today announced its ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

In a report released on February 26, Justine Telliez from Kepler Capital maintained a Hold rating on Idorsia Ltd (IDIA – Research Report), ...

Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call Idorsia will publish its Full Year ...

Good day and thank you for standing by. Welcome to the Idorsia Full Year 2024 Financial Results Webcast. At this time, all participants are in listen-only mode. After the speakers' presentation ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – February 26, 2025Idorsia Ltd (SIX: IDIA) today announced that the exclusivity agreement signed in November 2024 with an undisclosed ...

Idorsia Ltd (SIX: IDIA) today announced that it has published the agenda items for the bondholder meeting for holders of its outstanding convertible bond (ISIN: CH0426820350) (the Bonds or CB 2025) ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...